Correction: 'Liraglutide (VICTOZA): Add Another One to the List of "Do Not Use" Drugs for Type-2 Diabetes'

In our April 2011 Worst Pills, Best Pills News article about the inappropriately approved, dangerous new diabetes drug liraglutide (VICTOZA), there was an error in a paragraph describing interpretation of the results of the blood test hemoglobin A1c (HbA1c), which is used to assess the body’s control of sugar (glucose).

On page 5 of the newsletter, the last paragraph in the section entitled “The FDA’s approval of liraglutide” should have the following corrected last sentence:

"HbA1c is reported as a percentage, and it is now thought that a value between 7.0 and 7.5 percent is an acceptable goal, since higher [not lower] levels caused increases in overall mortality."